Brian K. Kaspar
Corporate Officer/Principal chez The Ohio State University College of Medicine
Profil
Brian K.
Kaspar is the founder of Milo Biotechnology LLC, which was founded in 2011.
He is currently an Associate Professor at The Ohio State University College of Medicine.
Previously, he worked as a Director & Chief Scientific Officer at Novartis Gene Therapies, Inc. Dr. Kaspar holds a doctorate degree from the University of California San Diego and an undergraduate degree from the University of Illinois.
Postes actifs de Brian K. Kaspar
| Sociétés | Poste | Début |
|---|---|---|
| The Ohio State University College of Medicine | Corporate Officer/Principal | - |
Anciens postes connus de Brian K. Kaspar
| Sociétés | Poste | Fin |
|---|---|---|
| AVEXIS INC | Directeur Technique/Scientifique/R&D | 01/05/2019 |
Milo Biotechnology LLC
 Milo Biotechnology LLC BiotechnologyHealth Technology Milo Biotechnology LLC develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The firm is targeting rare neuromuscular diseases, initiating a phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis. The company was founded by Al Hawkins and Brian K. Kaspar in January 2012 and is headquartered in Cleveland, OH. | Fondateur | - |
Formation de Brian K. Kaspar
| University of California San Diego | Doctorate Degree |
| University of Illinois | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Milo Biotechnology LLC
Milo Biotechnology LLC BiotechnologyHealth Technology Milo Biotechnology LLC develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The firm is targeting rare neuromuscular diseases, initiating a phase I/II clinical trial in Becker muscular dystrophy and inclusion body myositis. The company was founded by Al Hawkins and Brian K. Kaspar in January 2012 and is headquartered in Cleveland, OH. | Health Technology |
Novartis Gene Therapies, Inc.
 Novartis Gene Therapies, Inc. BiotechnologyHealth Technology Novartis Gene Therapies, Inc. developed gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. The firm’s robust AAV-based pipeline is used to provide advance treatments for Rett syndrome and Friedreich’s ataxia. The company was founded by John D. Harkey, Jr., David G. Genecov and John A. Carbona on March 8, 2010 and was headquartered in Bannockburn, IL. | Health Technology |
